IntroductionJanuary 14, 2019 – Study of the minuscule is not possible without aid of an instrument because the human retina does not possess sufficient angular resolution to discern microscopic detail at the focal lengths achievable by its natural lens. Thus the...
News
Pathologist vs Artificial Intelligence (AI): Competition or Collaboration?
December 3, 2018 – People may think that an automated artificial intelligence (AI) system for pathology that achieves a performance of 90 percent outperforms pathologists. However, pathologists are using microscopes for a task that includes complex computations –...
Flagship named Company of the Year by CIOReview
Westminster, CO — November 13, 2018 — CIOReview has named Flagship Biosciences “Company of the Year,” as part of the publication’s 2018 20 Most Promising Pharma & Life Sciences Tech Solution Providers industry review. “The ease of leveraging Flagship’s powerful...
GEN Features Flagship Solutions, cTA Platform
Westminster, CO – November 8, 2018 — Flagship’s precision medicine solutions and cTA® platform are featured in a recent GEN article, Precision Biomarkers and Medicines Go Global, summarizing highlights from the recent Clinical Biomarkers and World CDx conference in...
Flagship Presents at Pathology Visions 2018
November 4, 2018 – Flagship Biosciences will present its artificial intelligence (AI) driven pathology solutions at the Digital Pathology Association’s 2018 Pathology Visions conference, November 4 – 6, 2018, in San Diego, CA.
Flagship Recognized Among 10 Best Technology Solution Providers of 2018
October 31, 2018 – Flagship Biosciences is honored to be named by Industry Era Magazine as one of the 10 Best Technology Solution Providers of 2018. The Industry Era Magazine article, Connecting Patients with Life-saving Drugs, notes Flagship’s ground-breaking...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
Recent Posts
PUBLICATIONS
2018 Global AI-based Pathology Solutions in Immuno-oncology Technology Innovation Award
Based on its recent analysis of the global market for artificial intelligence (AI)-based pathology solutions in immuno-oncology (I-O), Frost & Sullivan recognizes Flagship Biosciences, Inc. (Flagship) with the 2018 Global Technology Innovation Award. Each year,...
Validation of a Muscle-Specific Tissue Image-Analysis Tool for Quantitative Assessment of Dystrophin Staining in Frozen Muscle Biopsies
Key Concepts: Flagship Biosciences’ MuscleMap algorithm that supports therapeutic development for DMD, a fatal neuromuscular disease, has been validated to be as effective as manual pathology. The study was published in the Archives of Pathology & Laboratory...
WHITE PAPER: Using Artificial Intelligence To Determine Patient Response To Immunotherapy
Key Concepts: While the current diagnostic strategies for PD-L1 checkpoint inhibitors identify some responders well, the majority of patients still need diagnostic approaches that better predict response. PD-L1 IHC remains a valuable tool for predicting patient...
EVENTS
Webcast – TissueInsight®: Realizing the Clinical Diagnostic Potential of Digital Pathology
View our Webcast Recording on TissueInsight®: Realizing the Clinical Diagnostic Potential of Digital Pathology. This recorded webcast will benefit pathologists and oncologists, attending physicians, image analysts, and those interested in digital pathology. Attendees...
SITC 2021
SITC 2021 Annual Meeting:Flagship plans to present a poster at the Society for Immunotherapy of Cancer (SITC) 36th Anniversary Annual Meeting, which is taking place both virtually and in person November 10-14, 2021 at the Walter E. Washington Convention Center in...
Webcast Recording: Tissue-Based CDx Development and Image Analysis in a Regulated Space
Recently Flagship hosted a webcast on Tissue-Based CDx Development and Image Analysis in a Regulated space. Our discussion stems from the fact that the United States Food and Drug Administration (FDA) requires comprehensive analytical validation and clinical...
